CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to deal with seizures related to a 3rd medical condition, increasing the vary of indications for the cannabis-derived treatment. Reports Hemp Industry Daily
The orally administered drug from Britain’s GW Pharmaceuticals beforehand was approved by the FDA to deal with seizures related to two types of extreme epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
The new FDA approval, granted July 31 to GW’s U.S. subsidiary, Greenwich Biosciences, means the drug can now be used within the United States to deal with seizures related to tuberous sclerosis complicated, a genetic illness believed to have an effect on one in 6,000 individuals.
Full story at. https://hempindustrydaily.com/fda-approves-gw-pharmaceuticals-cbd-drug-for-new-indication/?utm_medium=email&utm_source=newsletter&utm_campaign=HEMP_20200804_Daily&elqTrackId=BBD7264BE82DA0B9617E5F52303FFDD0&elq=ecbaa76fdaa0404db94caa1290c5173b&elqaid=3828&elqat=1&elqCampaignId=2734